January 20th 2023
Long-term survival benefit is seen in patients with treatment-naïve advanced esophageal squamous cell carcinoma who were treated with nivolumab plus chemotherapy or ipilimumab.
First-Line Nivolumab Combos Yield Improved OS Vs Chemo Alone in Esophageal Cancer
February 22nd 2022The CheckMate 648 trial found that using a combination of nivolumab and chemotherapy or nivolumab plus ipilimumab vs chemotherapy alone improved survival in advanced esophageal squamous-cell carcinoma.
Pembrolizumab Plus Chemotherapy Combination Improves Survival in Esophageal Squamous Cell Carcinoma
September 21st 2021Pembrolizumab plus chemotherapy compared with the placebo plus chemotherapy demonstrated an improvement in overall survival and progression-free survival for patients with esophageal squamous cell carcinoma.
Tiragolumab/Atezolizumab Demonstrate Promising Preliminary Activity in Metastatic Esophageal Cancer
July 12th 2021Preliminary data from the phase 1b GO30103 study indicated that the combination of tiragolumab plus atezolizumab may have promise in patients with heavily pretreated metastatic esophageal cancer.
Tislelizumab Improves OS Compared With Chemo in Advanced Unresectable or Metastatic ESCC
January 28th 2021The phase 3 RATIONALE 302 trial demonstrated that compared to chemotherapy, tislelizumab showed a statistically significant and clinically meaningful improvement in overall survival in the intention-to-treat population of patients with advanced or metastatic esophageal squamous cell carcinoma.
Young-Onset Esophageal Incidence, Advanced Disease Diagnosis on the Rise
January 6th 2021In addition to a concerning trend of increased rates of esophageal adenocarcinoma noted over the last 4 decades, this study also found that the proportion of those with advanced disease at presentation continues to rise for patients younger than age 50.
First-Line Ramucirumab Delays Progression in Gastric, Gastroesophageal Junction Adenocarcinoma
January 19th 2018First-line ramucirumab in combination with chemotherapy significantly improved progression-free survival in patients with metastatic gastric or gastroesophageal junction adenocarcinoma, according to results of the RAINFALL trial.
Robot-Assisted Esophagectomy Improved Postoperative Outcomes
January 19th 2018Patients assigned to robot-assisted minimally invasive thoraco-laparoscopic esophagectomy had fewer overall, surgery-related, and cardiopulmonary complications compared with open transthoracic esophagectomy, according to the results of the ROBOT trial.
Pembrolizumab Active in Heavily Pretreated Esophageal Tumors
November 29th 2017Treatment with the anti–PD-1 antibody pembrolizumab resulted in durable antitumor activity with manageable side effects in patients with heavily pretreated, PD-L1–positive advanced esophageal carcinoma, according to phase IB results of the KEYNOTE-028 study.
Adjuvant Chemo Improved Survival in Gastroesophageal Cancer
October 2nd 2017Treatment with adjuvant chemotherapy improved the overall survival of locally advanced gastroesophageal adenocarcinoma in patients treated with preoperative chemoradiotherapy and resection, according to the results of an analysis of the National Cancer Database.
PET Scans Helped Tailor Induction Chemotherapy for Esophageal Cancers
January 17th 2017Using PET scans during induction chemotherapy for esophageal cancer, researchers were able to assess patient response to treatment and adjust their therapy, leading to an improved rate of pathologic complete response prior to surgery.